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March 18, 2019 
Dear Dr. Roach, 
 
Please find a copy of our revised manuscript titled “Severity Assessment in CDKL5 Deficiency 
Disorder" by Demarest et al. attached to this upload.  We also provide details of how we have 
addressed the critiques by you and the reviewers. 
 
We appreciate the time and effort of you and the reviewers to provide us with feedback.  We have 
made adjustments that I hope address all concerns and improve the manuscript.  I would be happy to 
add supplemental file/information to the Delphi process at your direction if you feel the modifications I 
made to the text are not sufficient. I was hoping to strike a balance. 
 
Thank you for your consideration and we look forward to hearing from you. 
 
Sincerely yours, 
 
 
 
 
 
 
 
We appreciate the constructive criticisms of the reviewers and have modified the text 
appropriately.
Reviewing Editor
I appreciate reviewers' request for more information about your modified Delphi process, but I 
am not certain that I fully agree with it. It strikes me that all of this added detail might detract 
from the article's readability and clarity. What I might suggest would be to segregate this 
information into a supplementary file which would be available to anyone trying to drill deeply 
into your methods yet not muddy the water for everyone else.
We have been able to address Reviewer 1’s concerns in a succinct fashion by minor 
modifications of text in the methods and discussion.
Reviewer 1
Demarest et al present the development of an assessment tool for CDKL5 epileptic 
encephalopathy. The strengths of this study are the involvement of multiple stakeholders, 
including families, in the development of the assessment tool.  This is an emerging, vital, 
component for research of rare diseases that often require disease individualized assessments, 
with the challenge of developing an instrument in a small population.  There are a number of 
weaknesses of this study that include lack of detail on the evidence based review that guided 
the initial formation of the assessment tool, a significant lack of detail in the Delphi process 
itself, and no attempt to test the assessment to understand if it is useful or valid. This will be 
vital, if the investigators indeed wish to use this instrument in clinical trials. At present, it is an 
interesting questionnaire that could help standardize a history and physical, but does not 
comprise a valid instrument.
Please provide the literature that was used to form the basis of the initial items of the 
instrument. More detail is required on the Delphi process.  What percent of responses were 
needed to reach consensus? What items never reached consensus? How many items were 
contained in the second and subsequent rounds of the Delphi? What evidence based material 
was provided to participants to help guide their decision, and what strength of evidence were 
each item? A detailed description is needed of the discussion in reaching consensus.
We have added additional details to the text.  As noted in the methods, this was not conducted 
as a survey.  Participants were provided with the prior scales for other disorders, literature used 
and their own experience to guide the survey.  The instrument began with 24 items and 
converged by the 3rd and 4th rounds to ~50 items.
No attempt was made to test the utility of the instrument. Only 2 families trialed the instrument, it 
seems just for the amount of time needed to administer.  What investigations were performed to 
look at consistency and validity of the measure? A detailed investigation of intraobserver 
validity, validity over time (i.e. administration separated by 30 days to assess differences), item 
dependency (where two items are so correlated that they measure the same) and where 
possible, comparison to other gold standard instruments.
As noted in the discussion, this scale has not yet been validated.  We have noted the 
importance of this next step.  We have outlined the necessary approach detailed by the 
reviewer to address these issues.
Reviewer 2
The authors of this submission report the results of a multiple institution effort to devise a 
severity assessment tool for management and therapeutic intervention in the CDKL5 Deficiency 
disorder, utilizing a modified Delphi process. The tool was then presented at an International 
Foundation for CDKL5 family meeting for review and piloting and finally revision. The group 
stayed true to the Delphi process with the exception of not using an initial survey, but elicited 
feedback and created a consensus among a constant group of clinicians , researchers, industry 
representatives and patient advisory groups/parents involved in the disease.
The tool was developed with the concept that it must be utilized across a broad range of ages, 
and that the examination component would be possible in the average single visit appointment 
time of a pediatric neurologist. The tool is an important start for CDKL5 disease management for 
all the above parties.
The manuscript contains a number of grammatical errors , and abbreviations that are not 
intuitive across all cultures of the people likely to be reading this paper. Some are common to 
European readers and others to US readers, but certainly all should be referenced 
appropriately. 
We have proofed again for grammatical errors and utilized tools available for this within Word.  
We have removed infrequent abbreviations to improve readability.
The authors need to point out the availability of this instrument on-line and free of charge in the 
future if it is to be accepted in practice.
The CDD-SA is freely available for general use.  We have added this statement to the 
Discussion.
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Abstract
Background:  Pathological mutations in cyclin-dependent kinase-like 5 cause CDKL5 deficiency disorder 
(CDD), a genetic syndrome associated with severe epilepsy, cognitive, motor, visual and autonomic 
disturbances.  CDD is a relatively common genetic cause of early-life epilepsy.  A specific severity 
assessment is lacking, required to monitor clinical course, define the natural history and for clinical trial 
readiness.
Methods:  A severity assessment was developed based on clinical and research experience from the 
International Foundation for CDKL5 Research Centers of Excellence consortium and the NIH Rett and Rett-
related disorders Natural History Study consortium.  An initial draft severity assessment was presented 
and reviewed at the annual CDKL5 Forum meeting (Boston, 2017).  Subsequently it was iterated through 
four cycles of a modified Delphi process by a group of clinicians, researchers, industry, patient advisory 
groups and parents familiar with this disorder until consensus was achieved.  The revised version of the 
severity assessment was presented for review, comment and piloting to families at the International 
Foundation for CDKL5 Research sponsored family meeting (Colorado, 2018).  Final revisions were based 
on this additional input.
Results:  The final severity assessment comprised 51 items that comprehensively describe domains of 
epilepsy, motor, cognition, behavior, vision, speech and autonomic function.  Parental ratings of therapy 
effectiveness, child and family functioning are also included.
Conclusions:  A severity assessment was rapidly developed with input from multiple stake-holders.  
Refinement through ongoing validation is required for future clinical trials.  The consensus methods 
employed for the development of the severity assessment may be applicable to similar rare disorders.
Key words:  CDKL5; rare disorder; severity assessment; epilepsy; cortical visual impairment; intellectual 
disability.
Introduction
Pathological mutations in cyclin-dependent kinase-like 5 (CDKL5)[1-5] result in CDKL5 Deficiency 
Disorder Disorder (CDD, OMIM 300203, 300672, also referred to as CDKL5 Disorder, CDKL5 Syndrome and 
CDKL5).  Previously considered a “Rett variant”, this unique disorder [6, 7], has overlapping features with 
many of the developmental encephalopathies, disorders defined by genetic or presumed genetic etiology, 
severe seizures and intellectual/cognitive disability[8].  Incidence varies from ~1:40,000 -60,000[9-11]; 
approximately one-half to one-third as common as Dravet syndrome (1:20,000-50,000)[12, 13] or Rett 
syndrome (1:10,000 female births)[14].  Thus, CDD is a diagnostic consideration in young children with 
severe, early-onset epilepsy.
CDD is associated with high rates of severe epilepsy as well as cognitive, motor, visual and 
autonomic disturbances [4, 15-22].  Although surveys have reported the characteristics and frequency of 
CDD features[6], no clinical severity assessment has integrated CDD’s clinical manifestations.  
Assessments for Rett Syndrome[23-26], FOXG1[27], tuberous sclerosis[28], and other developmental 
epileptic encephalopathies[29, 30] incorporate many CDD features, but none provide a focused nor 
comprehensive assessment of CDD patients.  A specific severity CDD assessment targeting all clinical 
features is lacking and needed for clinicians to evaluate care, define natural history, inform specialist and 
therapeutic referrals, and with appropriate validation, to assess the outcomes of interventions in clinical 
trials.  Given the recent initiation of human therapeutic trials (CBD[31], Ataluren ClinicalTrials.gov: 
NCT02758626, ganaxalone ClinicalTrials.gov: NCT03572933, TAK-935 ClinicalTrials.gov: NCT03694275) 
and the reversibility of symptoms in CDD animal models[32], a validated assessment is urgently needed 
for CDD clinical trials.
We established a uniform clinical approach to patients as part of the International Foundation for 
CDKL5 research (IFCR) Centers of Excellence (COE) at three sites (Children’s Hospital Colorado/University 
of Colorado School of Medicine, Boston Children’s Hospital and Cleveland Clinic) and sites associated with 
the NIH-funded Rett and Rett-related disorders Natural History Study (NHS) (U54 HD061222; 
ClinicalTrials.gov: NCT00299312/NCT02738281).  Each site collects clinical or research data on CDD 
patients.  Application of scales and assessments developed for Rett syndrome were not adequate to 
capture unique features of CDD.  The CDD Severity Assessment (CDD-SA) intends to capture unique 
features of CDD, such as epilepsy severity, cognitive, motor and visual impairment and specific aspects of 
movement disorder.  This assessment needs to be comprehensive but efficient to administer.  It must 
capture the distribution of abilities of CDD patients without saturating.  Given the multiple stakeholders 
with overlapping goals for this type of assessment, we supplemented our clinical research infrastructure 
by recruiting into our group an international and multi-disciplinary panel of clinicians, researchers and 
industry professionals outside of the COE and NHS along with parents of patients directly involved in CDD 
patient advocacy groups.  This collaboration provided input to develop and refine the CDD-SA as described 
here. 
Methods
Clinically obtained or research-subject data available under IRB approvals (COMIRB 13-2020, 15-
2332, Cleveland Clinic IRB 14-478, need Boston COE IRB P00016602 and UAB NHS parent IRB F150518001) 
of 111 unique patients with CDD were reviewed.  Based on these data, review of available scales and 
literature noted above, an initial CDD-SA was developed by the principal investigator (PI: TAB) and 
presented at the annual CDKL5 Forum meeting (Boston, November 2017).  This was followed by an open 
forum allowing input from stakeholders for feedback and queries.  Revisions were made based on this 
input.  We questioned whether the CDD-SA should be for clinical or research purposes, the potential 
domains to assess, the optimal type(s) of response scale to use, and the time-frame of evaluation that is 
assessed (e.g., birth to present, prior 6 months to present, last month to present and last week to present).  
Domains considered to be relevant included:  overall severity of disorder, epilepsy, cognition, motor 
function, vision, autonomic disturbances and movement disorders.  Response scale that were considered 
included:  5-point scales (evaluating frequency or severity of a feature), Likert scales (evaluating the 
appropriateness of a statement) and global impressions of severity or change (caregiver- and clinician 
global impression scales).  We agreed that a clinical component provided by an examination was needed 
to complement and inform caregiver reported observations, leading to parent and clinician sections of 
the CDD-SA.  
The CDD-SA was then iteratively evaluated through four cycles of anonymous modified Delphi[33] 
comment and consensus by an international panel of clinicians, researchers, industry, patient advisory 
groups and parents familiar with CDD (Figure 1).  The group grew in numbers from those initially present 
at the Boston LouLou Foundation CDKL5 Forum to the full CDD-SA advisory group (SAAG, Table 1).  Each 
CDD-SA version was emailed to the group and returned to the PI with comments and suggested changes.  
The number of questions in each domain, the specific items in each domain and the wording of items 
were debated and modified to accurately reflect experiences of each group of contributors.  The number 
of items began at 24 and converged by the 3rd round to approximately 50 items, similar to the final.  The 
feasibility of applying the CDD-SA in a clinical setting led to a reduction of items in each domain.  The PI 
reviewed all comments, developed an independently ascertained best consensus from suggested 
changes, revised the CDD-SA and returned this to the review group with prior anonymous comments to 
provide historical background from the previous CDD-SA version.  This allowed the group to understand 
the rationale for emerging consensus and provide commentary as to whether the emerging consensus 
was tracking with the intended changes to the CDD-SA.  While this was not a survey-based approach like 
a traditional Delphi process the overall method of eliciting feedback and creating consensus was similar.  
The number of participants remained consistent throughout the review period, with no drop outs, 
providing a representative stakeholder input.  The penultimate CDD-SA version was presented by the PI 
at the IFCR annual meeting to parents of over 100 CDD patients (Denver, June 2018) for review, comment 
and trial.  All families present were provided access to the CDD-SA and comments were solicited and 
received for a duration of four weeks after the conference.  Two families (whose children were not 
managed by the PI) agreed to trial the CDD-SA at the meeting; the time to administer the CDD-SA was 
measured and collected.  The final revision of the CDD-SA was based on this additional input to result in 
the current CDD-SA (Figure 2).  There was full consensus by SAAG members on the final CDD-SA.
Results
After multiple revisions by the SAAG, the domains selected were epilepsy, cognition and motor, 
vision and autonomic function.  Movement disorders were included within the motor domain.  Clinical 
examination components were separated from the parent-report section within the cognition, motor, 
vision, and autonomic domains.  This allowed a combination of parent or caregiver-report and a clinician 
completed portion based on physical exam findings.  Parental components would be completed prior to 
the clinical examination; the time to complete this component has not yet been captured.  In a pilot clinical 
examination, the parent portion was reviewed and the clinical portion was completed in 30 minutes by 
each of the two volunteer families.  
Use of a global impression of severity[24] was rejected by the SAAG because these impression 
scales may rate self (caregiver)-described and patient-specific features that limit comparisons between 
patients.  Thus the clinical value of a global impression of severity may not translate to research settings 
and could be a limitation in that context.  The 5-point scale (0=normal, 5=most severe), similar to that 
used in the Rett syndrome Motor-Behavioral Assessment (MBA) [25] was selected, with higher scores 
more severe.  Likert scales were added, as a compromise to deletion of the global impressions scale, for 
ratings of overall child improvement and parent/caregiver resilience and adaptability (-5=worse, 0 = no 
change, 5=best possible) and evaluation of therapies (-5=worse, 0 = no change, 5=best possible).  
The SAAG determined that the CDD-SA evaluation time-frame should reflect developmental and 
longitudinal changes[20].  Use of the birth-to-present questions were limited since they could reflect 
ceiling effects or static assessments that would be insensitive to change.  Month-to-present time-frames 
were considered most likely to reflect accurate changes, though week-to-present time-frames could be 
substituted if a clinical trial required frequent assessments.  Since clinical assessments not part of a clinical 
trial may occur at 6-monthly intervals, 6-month to present time-frames were also included.
The wording of the items was simplified during the iterations substantially, especially in the 
epilepsy domain given the complexities of classifying seizures.  CDD is associated with multiple seizure 
types, including prolonged and atypical aura, epileptic spasms, tonic, tonic-clonic, myoclonic and atypical 
absence [18, 19, 22, 34-36].  Further, a single seizure may involve multiple types that evolve, while other 
seizures can be challenging to characterize even by experts using video EEG [37].  This feature of epilepsy 
associated with CDD makes traditional seizure counting difficult for parents and caregivers [38, 39].  
Rather, estimates of frequency and impact on function were agreed upon instead.  While this approach 
substitutes one subjective assessment for another, it becomes more patient-centered.  
The clinical portion was based on features typically evaluated during an exam by a pediatric 
neurologist.  However, certain CDD-SA components would likely add time to the routine visit, especially if 
that clinical visit includes a discussion of clinical decision making.  Regardless of the country and practice 
considerations, the CDD-SA had to provide relevant data that could be assimilated and utilized at a clinical 
visit.  The final domains and details of the exam were considered recommendations:  clinicians would 
tailor their approach such that not every item within their usual assessment would necessarily be included 
for all visits or all patients, although the items seek to limit clinician-to-clinician variability.  It can be 
challenging to assess the breadth of features and the functional impact of movement disorders within a 
clinical visit.  Also, any clinical examination is a snap-shot in time, and may not assess some areas captured 
for which extended observation by a parent or caregiver may be more informative.  There are similar 
challenges when assessing cognition and vision in CDD patients who are often non-verbal and have some 
degree of visual impairment.  Cognition assessment is limited by both exam time and CDD features to 
assessing choice and visual attention in the CDD-SA.
In summary (Table 2 and Figure 2), the final CDD-SA comprised 4 domains:  1) Epilepsy, 2) Motor, 
3) Cognition, Behavior and Vision and 4) Autonomic, that are nearly equally weighted with similar 
maximum scores (69, 65, 65 and 44, respectively) on items that mostly were scored on a 0 to 5 range.  
Impressions of overall improvement, parent/caregiver resiliency and therapy utility were each given a -5 
to 5 Likert scale.  An optional part of the CDD-SA was medical decision making.  While no points were 
assigned to each intervention, the goal was to provide a formulaic framework to track the impact of these 
when the CDD-SA is used in a primarily clinical setting.  Secondary scoring of data to reflect impact could 
be developed based on features such as patient discomfort and invasiveness, financial impact, impact to 
parent/caregivers, etc.
Discussion and Conclusions
Using a modified Delphi process, we developed a new clinically relevant and easily administered 
severity assessment (SA) for CDD (CDD-SA).  With on-going natural history studies such as the NIH-funded 
NHS and current and planned drug trials specifically for patients with CDD, our CDD-SA offers the ability 
capture aspects of this disorder that may change with time or in response to interventions.  In the first 
instance, we have provided some evidence for its content validity, basing the CDD-SA on available 
literature, the clinical and research experience of an international panel of experts and the lived 
experience of our parent participants.  We achieved a consensus across a broad spectrum of international 
clinicians from multiple specialties and subspecialties, parents, lay organizations and industry 
professionals to develop this CDD-SA .  
A limitation of the process was the lack of a framework with an objective ‘gold-standard’ to 
validate our CDD-SA.  Further, both the stakeholders and the PI could not reliably determine the relative 
value of specific recommendations, nor the validity of the scale to measure the feature of interest.   Bias 
by the PI in adjudicating disagreements and alternative views could be an inherent limit of this process 
but was countered by extensive expertise of the investigators and the lived experiences of families in the 
consultation process.  The SAAG input helped ensure the comprehensive and disease appropriate nature 
of the CDD-SA and it is unlikely that the primary domains will need major alterations in the future.  The 
SAAG-approved SA is being applied in CDD Centers of Excellence and can be applied in other clinical and 
research settings.  This will provide the basis for future validation that will include some refinement of 
necessary items and language.  In addition, qualitative data is needed to validate parental interpretations 
of questions and refine future versions in order to determine the sensitivity of the CDD-SA.  A quantitative 
dataset with a large sample size will be necessary to determine change with interventions, evaluate 
interrater reliability, factor analyses, stability and responsiveness over time. 
We propose that our clinical assessment will have immediate utility with clinicians who see 
children with CDD.  The CDD-SA is freely available for general use.  This methodology could be applied to 
the development of clinical assessments for other rare genetic disorders and the framework could 
potentially serve as an early foundation to other constituent organizations.  Key aspects that allowed this 
to happen included an initial framework (COE and NHS) that standardized the identification of clinical 
features relevant to CDD.  Next, those that were outside of the COE and NHS were included in the process.  
The support of patient advocacy groups and associated parents/caregivers provided mission-critical 
context.  Finally, a willingness to collaborate by the SAAG despite many other commitments and time 
constraints allowed the process to move forward.
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Table 2. Composition of the CDD-SA by domain and source of data
Domain By Caregiver # questions By Clinicians # questions Total # 
questions
1. Epilepsy Yes 15 No 0 15
2. Motor No 0 Yes 13 13
3. Cognition 
and Vision
Yes 1 Yes 12 13
4. Autonomic Yes 9 Yes 1 10
5. Overall Yes 2 No 0 2
6. Therapies Yes 1 No 0 1
7. Scale 
Scoring
No - Yes
8. Visit notes No - Yes
Figure 1:  Modified Delphi process for CDD-SA development.
Figure 2:  CDD-SA.  The Final CDD-SA with brief instructions on completion.
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PI created the initial CDD-SA based on clinical experience and research data
Initial CDD-SA was presented at the LouLou Foundation CDKL5 Forum
Followed by open discussion and feedback 
(Boston, November 2017)
CDD-SA revised by PI
Email based solicitation of 
feedback from SAAG
4 modified Delphi Cycles
Penultimate version was 
presented at the International 
Foundation for CDKL5 Research 
Annual meeting. 
(Denver, June 2018)
Two families at the meeting were 
trialed with the CDD-SA to assess 
the time required for 
administration.
(Denver, June 2018) 
CDD-SA was finalized by PI based on feedback at the IFCR meeting
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CDKL5 Severity Assessment (SA) 
 
Instructions to Parents/Caregivers and Clinicians: 
1) Focus on last 30 days.  Some questions also require review of last 6 months. 
 
2) Circle most appropriate number or response.  Keep in mind that larger numbers mean more severe. 
 
3) Parents/caregivers:  Fill out the BLUE and GREEN Sections PRIOR to your clinic visit to review DURING 
your clinic visit with your Clinician.  At FIRST visit, allow more time for Clinician to review terminology with 
Parents/caregivers to ensure that scoring is similar in future visits.  If an item is not answered, strike through 
the question. 
 
4) Clinician:  Review BLUE and GREEN Sections with Parents/caregivers.  Utilize examination findings to fill 
out ORANGE (examination) section.  Confirm YELLOW highlighted findings with parents/caregivers.  If an item 
is not answered, strike through the question. 
 
5) Clinician:  Utilize section totals to consider clinical decision-making. 
 
6) Clinician:  Utilize grey section as a template for clinical decision-making. 
 
Part 1: Epilepsy (Parental completion) 
(1) Frequency of NON-CONVULSIVE seizures, focusing on last 30 days: 
 Include ONLY for NON-CONVULSIVE: 
  Absences (unresponsiveness not interrupted by touch) 
  Auras (pre-seizure activity) that do not lead to a convulsion 
 
Never had any non-convulsive seizure = 0 
None > 6 months = 1 
Monthly (on average no more than 1 per month) = 2  
Weekly (on average, 2-4 per month) = 3  
Daily (on average, 5-30ish per month) = 4  
More than daily (more than 30ish per month) = 5  
 
(2) Frequency of CONVULSIVE seizures focusing on last 30 days: 
(Convulsive:  Tonic, tonic-clonic or drops that are disruptive and bothersome to patient or family. If the 
convulsive seizure changes during the event to spasms or jerks (or vice versa) DO NOT count the associated 
spasms or jerks separately below. For example, a hypermotor-tonic-spasms sequence is counted as 1 seizure 
in this question.) 
 
Never had any convulsive seizure = 0 
None > 6 months = 1 
Monthly (on average no more than 1 per month) = 2  
Weekly (on average, 2-4 per month) = 3  
Daily (on average, 5-30ish per month) = 4  
More than daily (more than 30ish per month) = 5  
 
 (3) ISOLATED Epileptic spasms and myoclonic jerks that cluster and are disruptive to patient or family (See 
note above, do not double count) focusing on last 30 days: 
 
Never had spasms or jerks= 0 
None > 6 months = 1 
Monthly (on average no more than 1 per month) = 2  
Weekly (on average, 2-4 per month) = 3  
Daily (on average, 5-30ish per month) = 4  
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More than daily (more than 30ish per month) = 5  
 
(4) Epileptic spasms and myoclonic jerks that don’t cluster and are not disruptive to patient or family focusing 
on last 30 days 
Never had spasms or jerks= 0 
None > 6 months = 1 
Monthly (on average no more than 1 per month) = 2  
Weekly (on average, 2-4 per month) = 3  
Daily (on average, 5-30ish per month) = 4  
More than daily (more than 30ish per month) = 5  
 
 (5) Number of seizure types in last 30 days: 
            Never had a seizure = 0 
One seizure type = 1 
Two seizure types = 2 
Three seizure types = 3. 
Four seizure types = 4  
Five or more seizure types = 5 
 
(6) Prolonged seizure, occurrence and duration of episode in last 30 days: 
(Prolonged seizures:  continuous convulsive seizure lasting more than 5 minutes multiple convulsive seizures 
lasting more than 5 minutes without resolution of consciousness between seizures) 
None ever = 0  
None in last 6 months = 1 
Once or twice in last 6 months = 2 
Once or twice in last 30 days = 3 
More than twice in last 30 days = 4 (on average, 2-4 per month) 
More than 5 times in last 30 days = 5 (on average, 5 or more per month) 
 
(7) Severity of prolonged seizures in last 30 days requiring use of rescue medications (use max score) 
 No use of rescue medication in last 30 days = 0 
 Used once in last 30 days = 1 
 Used twice in last 30 days = 2 
 Used 3x in last 30 days = 3 
 Used 4x in last 30 days = 4 
 Used 5 or more times in last 30 days = 5 
 
 (8) Severity of prolonged seizures in last 30 days causing hospital use (use max score) 
 No emergency department visits in last 30 days = 0 
 One emergency department visit in last 30 days = 1 
 Two emergency department visits in last 30 days = 2 
 Three or more emergency department visits in last 30 days = 3 
 Admitted once to hospital more than 24 hours in last 30 days = 4 
 Admitted to hospital and required ICU in last 30 days = 5 
 
(9) Number of anticonvulsants used during LIFETIME, not including rescue, VNS or Diet: 
None = 0 
One anticonvulsants = 1 
Two anticonvulsants = 2 
Three anticonvulsants = 3 
Four = 4 
Five or more = 5 
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(10) Current anticonvulsants used during LAST 30 DAYS, not including rescue, VNS or ketogenic diet: 
None = 0 
One anticonvulsants = 1 
Two anticonvulsants = 2 
Three anticonvulsants = 3 
Four = 4 
Five or more = 5 
 
(11)Current use of ketogenic diet in last 30 days (0 = never, 1 = past, 2= current): 
 
(12)Current use of VNS in last 30 days (0 = never, 1 = past and shut off, 2= current): 
 
(13) Subjective parental impression of seizures in last 30 days: 
Complete cessation (no evidence) of seizures = 0 
Partial improvement (at least 50% better) of seizures = 1 
Some but < 50% improvement in seizures = 2 
No improvement in seizures = 3 
Worsening of seizures = 4 
Most severe ever = 5 
 
(14) Subjective parental impression of seizures in last 30 days:  On average over the last 30 days, how many 
good days per week does patient have?  A “good” day may be defined as:  minimally disrupted by seizures or 
engaged, interactive, able to finish therapies throughout the day. 
 Hardly ever, it has been a really good month = 0 
 Only a few days this past month = 1 
 More than half of the days per week are good = 2 
 Always at least 2 or 3 days per week = 3 
 Maybe 1 or 2 good days per week = 4 
 Never has any good days per week = 5 
 
 (15) Longest seizure free period with focus on last 30 days 
 No seizures ever = 0 
 Greater than 6 months = 1 
 Greater than 1 month = 2 
 Greater than 1 week = 3 
 Greater than 1 day = 4 
 Always with daily seizures = 5 
 
Part 3: Cognition, Behavior, Vision and Speech (Parental completion) 
1) Spells of irritability that are disruptive to child, family or caregivers in last 30 days 
 No irritability = 0 
 Once or twice, not disruptive, consolable = 1 
 Once or twice, at least once inconsolable = 2 
 3-4 times, consolable = 3 
 3-4 times, at least once inconsolable = 4 
 More than 4 times, and/or more than twice inconsolable = 5 
 
Part 4: Autonomic (Parental completion) 
1) Swallowing abilities in last 30 days 
 Normal swallow = 0 
 Occasional choke/gag = 1 
More than 30 minutes to eat meal = 2 
 Feeding tube present, some oral = 3 
 Feeding tube only = 4 
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 Parenteral (intravenous) required OR diagnosed with aspiration pneumonia = 5 
 
2) Reflux 
 No issues = 0 
 Controlled, no medications (just diet, etc) = 1 
 Controlled, on medications as needed= 2 
 Controlled, on daily medications = 3 
 Impactful (uncontrolled or associated with patient distress) = 4 
 
3) Constipation 
 No issues = 0 
 Controlled, no medications (just diet, etc) = 1 
 Controlled, on medications as needed= 2 
 Controlled, on daily medications = 3 
 Impactful (uncontrolled or associated with patient distress) = 4 
 
4) Abnormal breathing (not associated with seizures) in last 30 days 
 No issues = 0 
 Occasional breath-holding or hyperventilating = 1 
 Daily breath-holding or hyperventilating = 2 
 Add 1 for cyanosis (blueness around mouth or face) 
 Add 1 for concern about this by parents or care-givers 
 
5) Toileting in last 30 days 
 Normal = 0 
 Timed for both = 1 
 Timed for 1 = 2 
 Diaper only = 3 
 
6) Pain responsiveness in last 30 days  
 Normal = 0 
 Delayed to minor = 1 
 Absent to minor = 2 
 Delay to major = 3 
 
7) Sleep in last 30 days (Please note:  Arousals occur in all children. Count arousals that the parents notice 
due to crying or other disruptions enough to awaken the parents.) 
 Normal, no issues = 0 
 Arouses less than once per week = 1 
 Arouses more than once per week = 2 
 Arousals require parental attention: add 1 
 Choose one of the following: 
  Most Arousals lasting 1-2 hours: add 1 
  Most Arousals/awake lasting > 2h: add 2 
 
8) Daytime sleepiness in last 30 days 
 Normal, no issues = 0 
 Rare but not disruptive (impactful to patient, teachers, family) = 1 
 1 day per week, disruptive (impactful to patient, teachers, family) = 2 
 2-6 days per week, disruptive = 3 
 7 days per week, disruptive = 4 
 Constant, throughout every day, disruptive = 5 
 
  
 Demarest et al, Figure 2 
9) Infections in last 30 days (include aspiration pneumonia also scored in question 4.1) 
 None, no issues = 0 
 Common, only 1-2 events, such as others in house also ill =1 
 One or more uncommon events (like aspiration pneumonia or urinary tract infection)  
  or more than 2 common events = 2 
 Choose one of the following: 
  Needing emergency department visit (not captured by that related to seizure):  
   Add 1 
  Needing hospitalization (not captured by that related to seizure): Add 2 
 
Part 5:  Overall impressions from caregivers (Parental completion): 
1) In the last month, OVERALL ISSUES with my child are better, worse or the same? 
 
-5 -4 -3 -2 -1 0 1 2 3 4 5 
Really worse     Same     Really better 
 
2) In the last month, the ADAPTABILITY OR RESILIENCE of caregivers at home is better, worse or the same? 
 
-5 -4 -3 -2 -1 0 1 2 3 4 5 
Really worse     Same     Really better 
 
 
Part 6: Therapies in last 30 days (Parental completion) 
Circle Therapy and fill in frequency 
 PT: ____ times per month; Increased, decreased or same (circle) in last 6 months 
 ST: ____ times per month; Increased, decreased or same (circle) in last 6 months 
 AT: ____ times per month; Increased, decreased or same (circle) in last 6 months 
 VT: ____ times per month; Increased, decreased or same (circle) in last 6 months 
 OT: ____ times per month; Increased, decreased or same (circle) in last 6 months 
 Feeding therapy (if separate from ST) : ____ times per month; Increased, decreased or same (circle) in 
last 6 months  
 Other_________________: ____ times per month; Increased, decreased or same (circle) in last 6 
months 
 Other_________________: ____ times per month; Increased, decreased or same (circle) in last 6 
months 
Definitions: PT = physical therapy, ST = speech therapy, AT = augmentative communication therapy (add 
here, even if part of ST), VT = vision therapy, OT = occupational therapy 
 
Rate the overall effectiveness of ALL therapies in last 30 days: 
 
-5 -4 -3 -2 -1 0 1 2 3 4 5 
Unhelpful     Same     Really helpful 
(Losing skills)    (maintaining skills)    (new skills learned) 
 
 
 
Part 2: Motor (Completed by Clinician, with input from caregivers where noted) 
1) Walk 
  Walks normally = 0 
  Walks independent, reduced ability, able to walk > 25 ft= 1 
  Walks independent, reduced ability, able to walk < 25 ft= 2 
  Walks with assistance (not independent) > 25 ft = 3 
  Walks with assistance (not independent) < 25 ft  = 4 
  Not walking = 5 
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2) Stands 
  Stands normally (including: goes from sit to stand) = 0 
  Stands, but some trouble, > 20s= 1 
  Stands 10-20s only = 2 
  Stands < 3s (no assistance) = 3 
  Stands only with assistance >3s = 4 
  Not standing (less than 3s with assistance)= 5 
 
3) Sits 
  Sits > 30s = 0 
  Sits < 30s = 1 
  Sits only with assistance (holding hips) = 3 
  Head control only, no trunk control = 4 
  No head control = 5 
 
4) Hypotonia  
  Normal = 0 
  Add for each: 
  Axial (+1) 
  Upper limb (+2) 
  Lower limb (+2) 
 
5) Weakness  
  Normal = 0 
  Add for each: 
  Axial (+1) 
  Upper limb (any:  +1; severe:  +2) 
  Lower limb (any:  +1; severe:  +2) 
 
6) Fine Motor  
  Normal hand use = 0 
  single pincer = 1 
  bilateral rake = 2 
  single rake = 3 
  Grabs only if object placed in hands or bats at objects = 4 
  No hand use = 5 
 
7) Dystonia (abnormal fixed position) and Rigidity (if in doubt, score higher) 
  Normal = 0 
  Add for each: 
  Upper extremities (+1) 
  Lower extremities (+1) 
  Constant (more than 50% of the visit and not intermittent or distractible) (+1) 
  Axial (+1) 
  Oro-facial (for example, grimace)(+1) 
 
8) Chorea and/or athetosis (if in doubt, score higher) 
  Normal = 0 
  Add for each: 
  Upper extremities (+1) 
  Lower extremities (+1) 
  Constant (more than 50% of the visit and not intermittent or distractible) (+1) 
  Axial (+1) 
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  Oro-facial (for example, oro-facial dyskinesia)(+1) 
 
9) Stereotypies: (abnormal movements of arms, hands or legs not better described by chorea or athetosis; 
count time when not distracted by no-no, other device or verbal distraction) 
  Not observed, not reported = 0 
  By report but not on exam = 1 
 Rare during exam = 2 
  Almost half of the exam = 3 
  More than half of the exam = 4 
  All, nearly all of the exam = 5 
  Describe (circle):  wringing hands, tapping/touching with hands, mouthing hands, flicking 
fingers, leg crossing, other:_______________________________________________ 
 
10) Impact of Dystonia/Rigidity, Chorea/Athetosis and Stereotypies 
  Not observed, not reported = 0 
  By report but not on exam = 1 
 Distractible and do not limit function = 2 
  Minor limit on function = 3 
  Impactful and interfering but some function present = 4 
  Major impact (example:  fully prevents hand use or sitting or walking) = 5 
 
11) Contractures-Arms 
  Fully flexible = 0 
  Loss of range, no effect on function = 1 
  Loss of range, somewhat tight, hard to dress, etc  = 2 
  Loss of range, very tight, very impactful = 3 
  No range, fixed in 1 arm = 4 
  No range, fixed in both arms = 5 
 
12) Contractures-legs 
  Fully flexible = 0 
  Loss of range, no effect on function = 1 
  Loss of range, somewhat tight, hard to dress, etc  = 2 
  Loss of range, very tight, very impactful = 3 
  No range, fixed in 1 leg = 4 
  No range, fixed in both legs = 5 
 
13) Curvature and Scoliosis (degrees noted on exam or Cobb angle measured on X-ray) 
  None = 0 
  Less than 10 = 1 
  10-20 = 2 
  20-40 = 3 
  > 40 = 4 
  Repaired = 5 
  
Part 3: Cognition, Behavior, Vision and Speech (Completed by Clinician, with input from caregivers 
where noted) 
2) Alertness and interaction during visit (minimum 20 minutes) 
           100 %, all of visit = 0;  
Not all of visit but more than half = 1 
Half of visit = 2 
Less than half of visit= 3,  
Not interactive (awake but “shut down”)  
  or sleepy for nearly all of the visit but not entirely =4 
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Not interactive (awake but “shut down”) or asleep during all of the visit = 5 
 Per the parent, was this typical (yes/no): 
 
3) Irritability or crying during visit (minimum 20 minutes) 
None of visit = 0;  
Rare but not more than half, consoles on own = 1 
Half of visit = 2 
More than half of visit, occasionally consolable= 3,  
Nearly all of the visit but not entirely, rarely consolable =4 
All of the visit, inconsolable = 5 
 Per the parent, was this typical (yes/no): 
 
4) Self-injury during visit (minimum 20 minutes) 
None of visit = 0;  
Rare but not more than half = 1 
Half of visit = 2 
More than half of visit = 3,  
Nearly all of the visit but not entirely =4 
All of the visit = 5 
 Per the parent, was this typical (yes/no): 
 Describe (biting self, hitting self, head banging, other): 
 
5) Aggressive behavior during visit (minimum 20 minutes) 
None of visit = 0;  
Rare but not more than half = 1 
Half of visit = 2 
More than half of visit = 3,  
Nearly all of the visit but not entirely =4 
All of the visit = 5 
 Per the parent, was this typical (yes/no): 
 Describe (biting others, hitting others, intentional spitting, other): 
 
6) Hyperactivity during visit (minimum 20 minutes) 
None of visit = 0;  
Rare but not more than half = 1 
Half of visit = 2 
More than half of visit, = 3,  
Nearly all of the visit but not entirely =4 
All of the visit = 5 
 Per the parent, was this typical (yes/no): 
 
7) Bruxism (during 20 minute exam) 
 Not observed, not reported = 0 
 By report but not on exam = 1 
Rare during visit = 2 
 Up to and almost half of visit = 3 
 More than half of visit = 4 
 Nearly all or the entire visit = 5 
 Per the parent, was this typical (yes/no): 
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8) Vision (acuity, function, attention, etc.) 
 OKN:  Suggested use of typical clinical tool and have been “calibrated” as normal by the clinician.  
Suggested use of OptOK app on ipad at full intensity in darkened room at 5-10 cm from eyes. 
 Normal vision, normal OKN = 0 
 Fixes and follows faces, reduced or ignored OKN = 1 
 Fixes, occasionally follows faces or objects= 2 
 Fixes only, no follow faces or objects = 3 
 Fixes only to bright light = 4 
 No visual attention = 5 
 
9) Eye movements: indicate all that are present 
 Normal (no points) 
 Add for each: 
  Dysconjugate, intermittent (add 1 point) 
  Dysconjugate, constant (add 2 points) 
  Horizontal or vertical nystagmus (add 1 point) 
  Roving (add 1 point) 
  Rotatory nystagmus (add 1 point) 
 
10) Speech 
 Full sentences, normal = 0 
 Phrases = 1 
 Words = 2 
 Single words or signs = 3 
 No words, only vocalizations = 4 
 No vocalizations = 5 
 
11) Non-verbal communication observed during minimum 20 minute visit (Parents must bring device to visit. 
Note or skip if left at home). 
 Points, propositive, normal; 4+ signs = 0  
3+ Signs = 1, or multiple choices with eye gaze or similar device = 1 
1-3 Signs = 1, or simple choices with eye gaze or similar device = 2 
Plays games with toy or object = 3 
 Intermittent play or interest with toy or object = 4 
 None observed = 5 
 
12) Two object choice during minimum 30s (2 toys or 2 foods or combo, verbal introduction) (Parents or 
clinician need to have on hand for visit.) 
 Verbal or instant reach and grab= 0 
Choice, reach and grab with < 5s delay = 1 
Choice, reach and grab with > 5s delay = 2 
Choice with reach only = 3 
Choice with eyes only (looks at what they want) = 4 
Unable to perform or No choices = 5 
 
13) Receptive language (allow 30s minimum of direct conversation) 
 Normal, follows 2 step commands, normal eye contact = 0 
 Follows 1 step command or abnormal eye contact = 1 
 Responds to voice with eye contact or similar (smiles, alerts, etc) for 5-20s =2 
 Responds to voice with eye contact or similar < 5s = 3 
 Inconsistent response to voice with eye contact or similar < 5s = 4 
Unable to perform or No eye contact or similar to voice = 5 
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Part 4: Autonomic (Completed by Clinician) 
Instructions:  Circle items if present (Strike through if not performed) 
10) Distension on exam:  add 1 
 Apnea seen on exam (prolonged auscultation):  Add 1  
 Oral cyanosis seen on exam:  Add 1 
Peripheral circulation (pull off socks or gloves, leave for 5 minutes before assessment) 
 Hands and feet warm and pink = 0 
 Cold hands:  add 1 
 Cold feet:  add 1 
 Purple or cyanotic hands:  add 1  
 Purple or cyanotic feet:  add 1 
 Abnormal skin (thin, atrophic, etc) associated with any above:  add 1 
 
Part 7:  Scoring (Compare to last visit) 
Part 1-Epilepsy total (max = 69): 
Part 2 Motor total (max = 65): 
Part 3 Cognition and Vision total (max = 65): 
Part 4 Autonomic/Other total (max = 44): 
Part 5 Overall/Resiliency total (range -10 to 10 ): 
Part 6 Therapy utility total (range -5 to 5 ): 
 
Part 8: Clinical Decision Making: 
Seen today by (circle): pediatrician, neurologist, developmental pediatrician, geneticist, epileptologist 
Circle aspects of plan 
 Anticonvulsant adjustment 
New therapy referral: OT, PT, ST, VT, AT, Feeding (if separate from ST) other:____________ 
Ophthalmology or vision referral  
 Referral to: epilepsy, movement, GI, pulmonary, orthopedics, physical medicine, developmental 
pediatrician, psychologist, sleep specialist, endocrine, gynecologist, immunologist, social work, 
other:______________________________________ 
Anticonvulsant monitoring (eg. CBC, liver panel, vitamin D) 
Other:   
 
EEG-routine EEG-overnight EEG- 2 days or more  ECG 
Holter Echo Sleep study Swallow study  Xray of back  Xray of limb 
